

NORTH CAROLINA DIABETES ADVISORY COUNCIL MEETING

6/1/2018

Sriram Machineni, MD
Assistant Professor of Medicine
Division of Endocrinology
University of North Carolina at Chapel Hill
Director, UNC Medical Weight Program



DISCLOSURE

- Consultant for Johnson & Johnson
- Advisory board for Rhythm pharmaceuticals
- Investigator on clinical trials with Novo-Nordisk



DIABETES REMISSION CLINICAL TRIAL (DIRECT)

Participant eligibility

- **DM diagnosed within 6 yr**
- BMI 27-45 kg/m²
- Age 20-65 yr
- HbA1c **6.0** to 12.0
- If HbA1c 6.0 to 6.5, they should be receiving anti-obesity medications



STUDY DESIGN

Exclusion

- **Insulin use**
- **HbA1c >12%**
- **Weight loss > 5 kg in past 6 months**
- eGFR <30 ml/min/1.732 m²
- Heart failure
- Anti-obesity medications, antipsychotic drugs
- Hospitalization for depression
- Substance abuse
- Pregnancy or consideration of pregnancy
- Bulimia



STUDY INTERVENTIONS

- Randomization of practices to weight management commercial program Counterweight –Plus or control
- Nurse or dietitian with 8 hrs of training
- 15 kg weight loss
- Low calorie diet 825-853 Kcal a day for 3 months
- Reintroduction phase of 2-8 weeks
- Maintenance program with monthly visits
- All the diabetes and hypertension drugs stopped on day one.



STUDY OUTCOME MEASURES

Primary Measures

- % of individuals who lost 15 kg weight
- % of individuals with **HbA1c <6.5 off meds (Remission rate)**

Secondary measures

- Quality of life (EQ-5D)
- Serum lipids
- Physical activity
- Program acceptability
- Sleep quality
- Blood pressure



STUDY RESULTS

- 49 primary care centers
- Intervention in 150, control in 149.
- 33 withdrew from the intervention group (**20%**)
- **149 from intervention group included in the analysis**



OUTCOME RESULTS


	Weight loss group	Control group	P value
% with 15 Kg wt loss	24%	0%	<0.001
Mean weight loss	10 kg	1 kg	<0.001
Remission of diabetes	46%	4%	<0.001
Mean HbA1c change	-0.9%	+ 0.1%	<0.001

	Weight loss group	Control group	P value
EQ- 5D	↑7.2 points	↓2.9 points	P<0.001 2
Triglycerides	↓0.31 mmol/L	↑0.09 mmol/L	P<0.001

Although average BP was the same reduced use of BP meds.



DIABETES REMISSION RATE PROPORTIONAL TO WEIGHT LOSS



HOW DO THE RESULTS COMPARE ?

Look AHEAD Study

- N=4503,
- Specialized setting and intensive follow up in intervention group.
- Average weight loss over control - 7.9% vs 8.7%
- Weight loss of >10% - 38% vs 61%
- Average HbA1c lowering 0.7% vs 0.9%
- Remission of diabetes at 1 yr 11.5% vs 46%

Look AHEAD remission criteria more stringent.

More uniform weight loss distribution in Look Ahead versus responders and non responders in DiRECT

Is it something special about the 800 Kcal diet ?



HOW DO THE RESULTS COMPARE ?

- Clinical experience of the Wake Forest Baptist Medical Center using Optifast program (comparable to Counterweight-plus).
- Average follow up 280 ± 160 days
- HbA1c reduced by 0.9% same as DiRECT
- Remission of Diabetes 48.7% vs 46%
- Mean weight loss 13.5 kg vs 10 kg



HOW DO THE RESULTS COMPARE ?

- Bariatric surgery in the STAMPEDE trial
- Sleeve Gastrectomy remission 27% vs 46% !
- Gastric bypass remission 42% vs 46% !

Is 800 Kcal diet as good as surgery ?

- Diabetes was more advanced in STAMPEDE (44% on insulin).
- Average duration of diabetes much longer
- Average HBA1c in STAMPEDE was 9.4 vs 7.6
- Remission criteria for STAMPEDE much more stringent.
- Using the <6.5 criteria- 39% and 36% at 5 yrs for bypass and sleeve respectively



FINAL THOUGHTS

- Shows a scalable option which can be administered from primary care offices with minimal training 8 hrs.
- A significant number of patients will not tolerate this intervention 20-25% even if motivated.
- 800 Kcal diets appear to have unique effects on diabetes- fantastic results in the SHORT term.
- Need to look at 2 yr and 5 yrs outcomes.
- Data very supportive of aggressive weight management solutions as **primary treatment** for diabetes type 2



THANK YOU

